{"id":"NCT02657434","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)","officialTitle":"A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-30","primaryCompletion":"2019-07-18","completion":"2022-12-13","firstPosted":"2016-01-15","resultsPosted":"2020-10-09","lastUpdate":"2023-11-21"},"enrollment":578,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Atezolizumab","otherNames":["MPDL3280A","TECENTRIQ"]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Pemetrexed","otherNames":[]}],"arms":[{"label":"Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed","type":"EXPERIMENTAL"},{"label":"Arm B (Carboplatin or Cisplatin + Pemetrexed)","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab in combination with cisplatin or carboplatin + pemetrexed compared with treatment with cisplatin or carboplatin + pemetrexed in participants who are chemotherapy-naive and have Stage IV non-squamous NSCLC. Eligible participants will be randomized by a 1:1 ratio into 2 groups: Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) and Arm B (Carboplatin or Cisplatin + Pemetrexed). The study will be conducted in two phases: Induction Phase and Maintenance Phase.","primaryOutcome":{"measure":"Progression Free Survival (PFS) as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)","timeFrame":"Randomization up to approximately 39 months","effectByArm":[{"arm":"Arm B (Carboplatin or Cisplatin + Pemetrexed)","deltaMin":5.2,"sd":null},{"arm":"Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed","deltaMin":7.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":15},"locations":{"siteCount":183,"countries":["United States","Argentina","Australia","Austria","Belgium","Bulgaria","Chile","China","France","Hungary","Ireland","Israel","Italy","Japan","Latvia","Lithuania","Malaysia","Netherlands","Peru","Portugal","Romania","Russia","South Korea","Spain","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["36795388","36052772","35511917"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":91,"n":274},"commonTop":["ANAEMIA","NAUSEA","CONSTIPATION","DECREASED APPETITE","FATIGUE"]}}